IDEXX Laboratories reported third-quarter revenue of $1,214 million, a 10% increase as reported and organic, driven by double-digit growth in Companion Animal Group diagnostics recurring revenue. Diluted earnings per share reached $4.01, up 18% as reported and 22% on a comparable basis, supported by operating margin expansion of 100 basis points to 33.1%. The company raised its full-year 2026 revenue guidance midpoint by $32 million to $4,754 million and increased the EPS outlook range to $14.96-$15.16, reflecting strong operational performance and acquisition impacts from CoVet. IDEXX Laboratories is a global leader in pet healthcare innovation, providing diagnostic and software products and services to the veterinary community.
